Rankings
▼
Calendar
FULC Q2 2021 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FULC
Fulcrum Therapeutics, Inc.
$436M
Q2 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
+119.0% YoY
Gross Profit
-$13M
-296.7% margin
Operating Income
-$20M
-449.3% margin
Net Income
-$20M
-448.5% margin
EPS (Diluted)
$-0.60
QoQ Revenue Growth
-8.5%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$18M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$138M
Total Liabilities
$27M
Stockholders' Equity
$111M
Cash & Equivalents
$57M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4M
$2M
+119.0%
Gross Profit
-$13M
-$11M
-20.6%
Operating Income
-$20M
-$16M
-23.6%
Net Income
-$20M
-$16M
-25.3%
← FY 2021
All Quarters
Q3 2021 →